
Akoonu Awọn Iyipada Paradigm ni Itọju Ẹdọfóró Akàn Aiṣiṣẹ Ailoye Tumor-Infiltrating Lymphocyte (TIL) Therapy Bispecific Antibodies: The Dual-Target Approach Comparative Analysis of Eme...
Oye Akoonu Loorekoore Akàn Ẹdọfóró ni 2026 Titun Awọn Itọsọna NCCN fun Loorekoore Awọn Itọju Arun Akàn Ẹdọfóró Loorekoore fun Awọn ilana Akàn Lung Loorekoore fun EGFR-Mutant Recu…
Oye Akoonu Indolent Akàn Ẹdọfóró ni 2026 Yipada Paradigm: Lati Iṣẹ abẹ Lẹsẹkẹsẹ si Iwoye Iṣiṣẹ Iṣeduro Awọn aṣayan Iṣẹ-abẹ Invasive Kere fun Awọn Egbo Ilọsiwaju ti o farahan T…
Oye Akoonu Ipele 2A Akàn Ẹdọfóró Ẹdọfóró Ẹdọgbọn Kekere 2026 ELCC Breakthroughs ni Neo-Adjuvant Strategies Itọju Awọn Itọju Iwakọ fun Ipele Iyipada Iwakọ 2A Iṣayẹwo Iṣalaye Akàn Ẹdọfóró ti Trea...
Akoonu Itankalẹ ti Ipele Itọju Ẹdọfóró Ẹdọfóró Ipele Kekere Iza-bren: Iyipada Paradigm ni Bispecific ADC Therapy Tarlatamab ati Dide ti T-Cell Olukoni Aabo ati Ifarada ni...
Oye Akoonu Loorekoore Akàn Ẹdọfóró ni 2026 Titun Awọn Itọsọna NCCN fun Loorekoore Awọn Itọju Arun Akàn Ẹdọfóró Loorekoore fun Awọn ilana Akàn Lung Loorekoore fun EGFR-Mutant Recu…